Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis

What Was Tested

In this not phased trial, researchers set out to test Desmopressin.

Nocturnal Enuresis (NE) is defined as the involuntary passage of urine during sleep past the age of usual control, which is considered a developmental age of 5 to 7 years.

NE is a common problem that causes distress to both children and their families.

It has an adverse impact on behavior and social life, affects self-esteem, and can result in poor emotional well-being.

It had 1 arm (groups): Desmopressin (experimental).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 50 planned participants were the target.

It was open to people of any sex aged from 7 years up to 14 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: School age group (from 7 to 14 years). Primary monosymptomatic nocturnal enuresis.

The full record lists 2 inclusion and 6 exclusion criteria; among the exclusions: diurnal enuresis; urinary tract infection within the preceding 3 months; diabetes mellitus.

How the Study Was Run

Design: single-group and open-label.

Being open-label, the Desmopressin study did not mask who received what.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2024-02-23 with completion listed for 2024-05-01.

It ran at 1 site in Egypt.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: The number of episodes per week after desmopressin treatment (time frame: After the end of the treatment for one month).

What This Means in Plain Language

Put simply, this is a not phased trial of Desmopressin in 50 people.

Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Desmopressin compound page, all human trials.